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1. Introduction 
Although radiation therapy (RT) can be very beneficial in a number of cutaneous 
malignancies, it tends to be a relatively underutilized therapy for a number of reasons. The 
hesitancy on the part of dermatologists to recommend RT is driven by a number of issues. First 
and foremost is perception inherent in dermatology training programs. All dermatologists in 
training encounter patients harmed by the historic overutilization of RT in the past, both by 
dermatologists themselves and radiation oncologists for non-malignant inflammatory diseases 
such as eczema, acne, and even fungal infections. Many patients treated in their youth with 
Grenz rays by dermatologists have gone on to develop multiple cutaneous malignancies later 
in life. As the role of ultraviolet light in carcinogenesis has come into focus, it can be 
intellectually awkward for dermatologists to discourage patients from excessive exposure to 
ultraviolet light and then recommend radiation therapy, especially in the younger population 
due to perceptions of the consequential increased risk for the latent development of further 
skin cancers. Dermatologists may focus too much on the carcinogenic consequences of RT 
(which are statistically quite modest) at the expense of the therapeutic benefits of RT. Another 
perceptual issue is radiated sites can be characterized by atrophy and telangiectasia which are 
cosmetically undesirable. Finally, familiarity with standard treatments within the bailiwick of 
dermatology training (excisional and Mohs micrographic surgery, laser surgery, cryosurgery, 
curettage and electrodessication, and medical therapies such as topical 5-fluorouracil and 
imiquimod cream to name a few), are naturally going to be considered first by a dermatologist 
who is well-versed in these therapies but is relatively unfamiliar with state of the art 
approaches currently utilized by radiation oncologists.  
For these and other reasons, RT is a mostly underutilized treatment modality for many 
varieties of skin cancer and can have both high cure rates with excellent cosmetic outcomes. 
This chapter will address the most commonly encountered cutaneous malignancies where 
RT could be considered as either a first line or adjuvant treatment with acceptable side effect 
profiles. It remains the obligation of dermatology and radiation oncology training programs 
to better communicate and discuss the issues surrounding the indications for and selection 
of RT for skin cancers. 
2. Basal cell carcinoma  
Basal cell carcinoma (BCC) is, by far, the most common of all cancer types in Caucasians 
with increased rates directly tied to latitudes approaching the equator (Fears & Scotto, 1983). 
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Although metastases are very rare with BCC, the tumors are often in cosmetically sensitive 
areas of the face, scalp, and neck, and represent a major cause of morbidity and take out a 
major chunk of the health care expenditure pie. The annual cost of treating BCC and 
squamous cell carcinoma (SCC) in the Medicare population in the United States is estimated 
to be above $400 million (Liu & Chen, 2000; Mudigonda et al., 2010).  
2.1 Epidemiology 
There were an estimated 2 million cases of non-melanoma skin cancer diagnosed in the 
United States in 2010 (Edwards, 2010) and of those, 75-80% are BCC (Lang & Maize, 2005). 
The incidence of BCC continues to rise worldwide in the Caucasian population and is 
thought to be mainly a consequence of increased exposure to ultraviolet light.  
2.2 Etiology 
Ultraviolet light is the causative factor in the majority of BCC and risk is inversely related to 
inherent melanin content in the skin which serves a protective function. It is uncommon for 
blacks to get BCC, but if blacks suffer from albinism where the melanocytes fail to 
manufacture melanin, the risk for BCC increases substantially (Alexander & Henschke, 
1981). Multiple BCCs can be seen in a few scenarios such as patients undergoing RT for acne 
or for other inflammatory conditions in their youth. Doses as low as 450 rads have been 
associated with the formation of BCC, and in some patients, very high numbers of tumors 
(Everall & Dowd, 1978). Ultraviolet light therapy given by dermatologists for inflammatory 
conditions such as psoriasis has also long been known to increase BCC risk (Halprin, 1980; 
Roenigk et al., 1981; Stern et al., 1979).  
2.3 Clinical presentation 
The three most commonly encountered subtypes of BCC are the nodular, superficial, and 
morpheaform variants. The nodular BCC most commonly presents as a nodule that 
resembles a drop of paraffin wax riddled with telangiectasia. Sometimes the center will 
begin to necrose and a central ulcer/eschar develops with a surrounding rolled edge (See 
Figure 1a). The superficial BCC is completely different and presents as a red scaling macule  
 
Fig. 1a. Basal cell carcinoma with paraffin wax like opalescence, telangiectasia, and 
ulceration 
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that often features notching at the border. Clinically the superficial BCC can be confused 
with actinic keratosis, nummular eczema, and even tinea (ring-worm). The morpheaform 
BCC is different still and often is scar-like and depressed compared to the surrounding skin, 
similar to a compressed snowshoe print. The surface is often shiny as the pores are 
frequently obliterated by the tumor. 
2.4 Histology 
The nodular BCC will have a pattern of palisading basophilic basal cells that extend off of 
the dermoepidermal junction and expand into the dermis. At the leading edge of the 
expansile tumor mass there is often a thin layer of degradation of the matrix leaving a 
retraction artifact between the tumor and the surrounding dermis. The tumor slowly 
dissolves the collagen as it glacially makes its way through the dermis (See Figure 1b). The 
superficial BCC is similar but has only small buds of the palisading basal cells extending off 
of the epidermis and lacks the deeper dermal infiltration. The morpheaform tumors arise in 
a scarred and fibrotic matrix and the basal cells are grouped into numerous thin and 
filamentous strands surrounded by sclerosis, giving an overall pattern similar to paisley. 
Since such tumors are much more filamentous and embedded in a sclerotic stroma, they are 
much less amenable to removal with a curette. 
 
Fig. 1b. Histology of basal cell carcinoma 
2.5 Treatment 
The majority of BCCs are treated with curettage and electrodessication (CE). CE is not 
considered for morpheaform tumors, recurrent tumors, large tumors (> 2 cm) or tumors in 
thickly hair-bearing areas such as the scalp due to lower success rates. Simple excision is 
also a viable treatment option with cure rates similar to CE (Werlinger et al., 2002). Of all 
treatment modalities applied to BCC, Mohs micrographic surgery (MMS) has the highest 
documented cure rates (approximately 99% for most tumors) compared to 90-93 % cure 
rates for other modalities (Rowe et al., 1989). Pioneered by the late Fredrick Mohs, M.D. of 
the University of Wisconsin, MMS involves a staged excisional approach where the visible 
tumor is removed and then submitted for fresh tissue frozen sections. Areas of tumor 
positivity are recorded by the Mohs surgeon who then returns to the patient and removes 
additional tissue confined to specific tumor roots. This process is repeated until 
histologically negative margins are verified, and only then is the defect surgically repaired. 
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The great strength of this procedure is the reduction of the removal of uninvolved tissue to a 
bare minimum (as opposed to a wide local excision), combined with very high cure rates. 
The main drawbacks of MMS are that the surgeries can be very morbid, especially when key 
anatomic structures are partially or completely removed as part of the surgery in areas on 
the nose, eyelids, ears, and lips. Although there have been ingenious advances in 
reconstructive surgery, the Mohs surgeon and facial and plastic reconstructive surgeons are 
left facing many surgical defects where the reconstructive options are limited. In such cases, 
radiation therapy can be a very desirable alternative to radical surgical excision.  
2.6 Radiation therapy 
Radiation therapy (RT) is not used as frequently as in the past, but it remains a very 
important part of the armamentarium for treating BCC. The chance of success is directly 
related to the clinician’s ability to delineate tumor margins so the lesion is not undertreated. 
It has been suggested that in tumors with ambiguous borders, scouting biopsies be 
performed prior to embarking on RT to better define the required field (Lang, 2005). With 
respect to primary therapy, RT has the great advantage of avoiding reconstructive surgery 
in critical sites around the lacrimal system and on the nose and ears. (Chahbazian 1984; 
Leshin et al., 1993; Morrison et al., 1997). Many patients with BCC are poor surgical 
candidates due to advanced age and co-morbidities, and surgery becomes impractical. Some 
BCCs are not resectable even in healthy patients and RT is a viable alternative to surgery 
and, as will be discussed, is curative in most cases (about 95%). In some circumstances, RT 
may not be curative but palliation is an important consideration for large and complicated 
tumors. (RD, 1985).  
RT has been discouraged in young patients in a wide range of reports (Brady, 1987; Braun-
Falco, 1976; Chahbazian, 1980, 1984; Gladstein, 1978; Thissen, 1999), as there are concerns of 
the latent eruptions of cancer in the irradiated site as well as the tendency for treated sites to 
develop atrophy and telangiectasias over time that compromise the cosmetic appearance. As 
predicted, the size and extent of tumor will determine the success rate and long-term 
cosmetic result. RT has also been discouraged for morpheaform tumors. (Brady et al., 1987; 
Braun-Falco et al., 1976; Chahbazian, 1980, 1984; Dubin, 1983; Gladstein et al., 1978). There 
has also been reluctance to treat patients with the basal cell nevus syndrome who harbor a 
genetic defect in the PTCH tumor suppressor gene where RT may create additional DNA 
damage, creating higher risk for additional tumor formation. (Gorlin, 1987).  
Table 1 is included by permission of the National Comprehensive Cancer Network 
(NCCN Guidelines®, 2011) with the following clarifications. Because of the wider beam 
penumbra, wider field margins are necessary when using electron beam than with 
orthovoltage X-rays. If lead skin collimation is used, tighter field margins can be used 
with electron beam adjacent to critical structures such as the lacrimal system. When using 
electron beam, bolus is necessary to achieve adequate surface dose. An electron beam 
energy should be chosen which achieves adequate surface dose and encompasses the 
deep margin of the tumor by at least the distal 90% line. Electron beam doses are specified 
at 90% of the maximal depth dose (Dmax). Orthovoltage X-ray doses are specified at 
Dmax (skin surface) to account for the approximately 10% higher biologic effectiveness 
between the two modalities of radiation.  
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Table 1. Dose Recommendations for Primary BCC and SCC 
When the proper patient is selected and RT is expertly executed, response rates are excellent. 
The five-year complete response rates have been reported to range from 90 to 95%. A study 
looking at 862 primary BCCs treated with RT alone had a five-year complete response rate of 
92.6%. (Silverman et al., 1992). Increasing diameter was associated with recurrence risk with 
95.6% cure rates for tumors < 10 mm on the head, but cure rates of 90.5% if the tumors were > 
10 mm. (Silverman et al., 1992). Long-term cosmetic outcomes were evaluated in this study 
and were thought to be satisfactory in 63% of RT-treated patients, 84% for patients who had 
surgery, and 91% with those treated with curettage and electrodessication. (Silverman et al., 
1992). The data on the cosmetic outcome supports the notion that RT ought not to be a first line 
therapy for young patients if other options are available.  
The general consensus in the literature appears to support the notion that tumors < 10 mm 
can be effectively treated with one dose of radiation. Mendenhall et al. recommend a single 
dose of 20 Gy, typically reserved only for when late cosmesis is not important and travel for 
the patient is exceedingly difficult. (Mendenhall et al. 1994). However, fractionation is 
recommended for tumors > 10 mm due to the improvement in the therapeutic ratio, 
allowing for less harm to surrounding normal tissue despite a larger biologically effective 
dose to the tumor.(Lang & Maize, 2005). Fractionation is particularly important for tumors 
overlying cartilage such as the nose and ears, or over bone. Additional considerations when 
choosing the extent of fractionation include patient convenience and performance status. For 
lesions < 3 cm where cosmesis is unimportant, 40 Gy in 8 fractions and 30 Gy in 5 fractions 
may be considered (Morrison et al., 1993).  
The treatment of recurrent tumors with RT is not as effective as it is for primary tumors, 
which is also true for (MMS). In a study of 221 recurrent tumors that were subsequently 
treated with RT, the re-recurrence rate was 9.5%. (Silverman et al., 1992). In a second study 
treating 61 recurrent BCCs with RT the 5-year estimated Kaplan-Meier re-recurrence rate 
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was 4% for tumors < 10 mm and 19% for tumors > 10 mm with a cost that was roughly 
equivalent to MMS. (Wilder et al., 1991). These data were further stratified by stage where 
Kaplan-Meier 5-year predicted recurrence rates for stage I/II tumors (tumors of any size but 
confined to the skin) was 7% compared to a 58% predicted recurrence rate for tumors that 
were stage III/IV (tumors that invaded underlying bone, muscle, or cartilage)(Wilder et al. 
1991). The authors emphasize that tumor stage (depth) is much more important than actual 
tumor size (diameter) in predicting responses to RT. 
In summary, RT can be a very effective treatment for BCC and even recurrent BCC, but 
patient selection is critical as is the cooperation between the Mohs surgeon and the radiation 
oncologist in making every effort possible in delineating tumor margins in order to inform 
decisions about field sizes. This may include several scouting biopsies in order to estimate 
tumor perimeters. RT is particularly well-suited for the elderly or frail patient who is a poor 
surgical candidate but should be used with great caution in younger patients who may have 
a poor long-term cosmetic outcome. RT gives the great advantage of avoiding surgical 
morbidity to critical sites on the nose, eyelids, ears and lips where reconstructive options are 
limited. Since RT is frequently fractionated, some patients may balk at the need to make 
several trips to a medical center for treatment, but others jump at the chance to avoid an 
invasive surgical approach.  
3. Squamous cell carcinoma 
Squamous cell carcinoma (SCC) is the second most common cutaneous malignancy behind 
BCC and also occurs in chronically sun-exposed sites, particularly the head and neck. Unlike 
BCC, SCC does have significant metastatic potential and with the advent of solid organ 
transplantation, has become a significant risk for morbidity and mortality in that 
population. SCC is also more frequently associated with underlying states of chronic 
inflammation such as burn scars, chronic ulcers, chronic thermal injury, and exposure to 
chemical carcinogens such as arsenic and polycyclic hydrocarbons.  
SCC begins with the squamous cells in the epidermis which are situated directly above the 
basement membrane where the basal cells are located in the stratum basale (See Figure 2). 
Historically, the layer of the epidermis containing the squamous cells is called the stratum 
spinosum, which takes its name from the observation under high power light microscopy of 
desmosomes emanating off of the squamous cells like “spines.” Also known as the 
keratinocytes, the squamous cells undergo an abrupt transition in the stratum granulosum 
of the epidermis where the intracellular keratin filaments clump, the cell undergoes 
programmed death, and a keratogenous shell remains with intercellular wax esters acting 
like “mortar” between the keratinocyte “bricks” forming the watertight barrier of the outer 
layer of the skin, the stratum corneum. Because of the abundance of keratin protein in 
squamous cells, in general, SCC is clinically much more scaly and crusted than BCC.  
3.1 Incidence and epidemiology 
SCC accounts for about 10-20% of all skin cancers (Nguyen, 2005), with an incidence of 
approximately 700,000 cases per year in the United States with 2500 expected deaths in 
2010.(Foundation, 2011). 80% of SCC occurs on sun-exposed sites such as the head and neck, 
and upper extremities. (Nguyen, 2005). Although BCC outnumbers SCC by 4:1, SCC is  
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Fig. 2. Schematic diagram of human epidermis 
responsible for the vast majority of non-melanoma deaths. In the general population, the 
rates of SCC have shown a doubling of the incidence over the last 40 years. (Stern, 1978). 
SCC is becoming a more common problem among solid organ transplant recipients and in 
patients with lymphoproliferative malignancies, presumably due to decreased 
immunosurveillance. A renal transplant recipient has an increased risk of developing SCC 
in the first year of 7%, 45% risk after the first 11 years following transplant, and 70% risk 
after 20 years. (Bouwes Bavinck et al., 1996). The situation is worse for heart transplant 
recipients who have a 2-3 times greater risk of SCC than do renal transplant patients.  
Risk factors for the development of SCC include fair-skinned patients with risk associated 
with increasing rates of chronic cumulative UV exposure, living in areas of decreasing 
latitude, increased altitude, prior history of non-melanoma skin cancer, male gender (men 
are 2-3 times more affected than females), and age > 50. (Nguyen, 2005).  
3.2 Etiology  
The majority of SCC are caused by mutations induced by ultraviolet light exposure, most 
notably in the tumor suppressor gene p53. (Sarasin & Giglia-Mari, 2002). A smaller 
percentage of SCC are not related to UV injury, but rather will occur as a result of sites of 
chronic skin inflammation which can result from a number of causes such as chronic 
inflammatory skin diseases, particularly non-healing ulcers. Traumatic insult to the skin 
such as scar tissue from cuts or thermal or chemical burns has also been associated with 
SCC. Ionizing radiation as mentioned in the introduction is clearly associated with increased 
SCC risk as is chronic lymphedema. 
Also implicated in the formation of SCC is exposure to chemical carcinogens. Polycyclic 
aromatic hydrocarbons such as soot, pitch, tar, oil shale, and mineral oil have all been 
documented associations with SCC. Arsenic has long been appreciated as having a causal 
link with SCC. (Baca & Dzubow, 1998).  
3.3 Clinical presentation 
Because squamous cells produce keratin protein which is a key feature in the barrier 
function of the skin, well-differentiated SCC will be associated with a degree of 
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hyperkeratosis with the clinical correlation of scale (See Figure 3a). As SCC becomes less 
well-differentiated, they often lose the ability to produce keratin with the clinical correlation 
of loss of scale and the tumors take on a more erosive appearance not unlike a stewed 
tomato. The distribution of SCC, as anticipated, favors chronically exposed sites such as the 
head and neck where 70% of SCC are found and another 15% occur on the upper 
extremities. (Nguyen, 2005). SCC frequently occurs in the setting of stigmata of chronic sun 
exposure such as multiple actinic keratosis (AK), which are small patches that are usually 
red in color and have a slightly roughened surface similar to fine grained sand paper. SCC 
of the lip has long been recognized as being generally more aggressive, with higher rates of 
metastases than the other head and neck locations, and is more likely found on the lower lip. 
(Dinehart & Pollack, 1989). Cigarette and pipe smoking have also been associated with 
increased rates of lip SCC. (Pentenero et al., 2011).  
 
Fig. 3a. Squamous cell carcinoma 
Verrucous carcinoma is a variant of SCC that clinically presents as a warty growth that may 
simulate the surface of a cauliflower. It may occur on the digits, oral mucosa, feet, or the 
anogenital region where it is known by the eponym “Buschke-Lowenstein tumor.” 
(Schwartz, 1995). Although such tumors may be locally disfiguring, they are less likely to 
metastasize compared to other SCC subtypes. (Nguyen, 2005).  
Bowen’s disease is a in situ variant of SCC that presents as an erythematous patch with thin 
superficial scaling and frequently has notching of the borders which helps to distinguish it 
from nummular eczema, tinea corporis, or psoriasis. When Bowen’s disease occurs on the 
penis, it has been known in the past as erythroplasia of Querat (Aynaud et al., 1994) 
although more recently, it has been suggested that the terms “Bowen’s disease” and 
“erythroplasia of Querat” should not be used for lesions in the anogenital region and the 
preferred terms are vulval intraepithelial neoplasia for females and penile intraepithelial 
neoplasia for males( Wilkinson, 1992). Although an in situ tumor, Bowen’s disease can 
progress to become an invasive SCC, particularly when it occurs at genital sites.  
Although metastases from SCC are statistically much less likely than with melanoma, SCC 
can metastasize with fatal consequences. Regional metastases have an overall 5-year 
survival of 25% (Nguyen, 2005) and are a particular problem on the head and neck when 
SCC invades the perineurium of cranial nerves and gains access to the brain via foramina in 
the cranium. SCC also spreads via lymphatic channels to involve regional lymph nodes, and 
from there can gain access to the blood vessels with consequential distant metastases to 
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internal organs. The overall risk for metastases ranges between 2-6% (Nguyen, 2005), but 
may be associated with factors such as anatomic location, whether the tumor is primary or a 
recurrence after aggressive therapy, differentiation (well- or poorly-differentiated 
histologically), the presence of perineural invasion and the size of the diameter of the 
involved nerve, and the underlying immune status of the patient. Of head and neck sites, 
the ears and the lips confer higher risk for metastases at 8.8% and 13.7% respectively. 
(Nguyen, 2005; Ponten, 2003). The disparity in metastatic risk is dramatically increased 
between primary SCC (5.2% risk) to a 30.3% risk for recurrent tumors. (Nguyen, 2005). 
Increasing size also confers increasing risk where SCC  <2 cm has a metastatic risk of 9.1% 
compared to 30.3% for tumors > 2 cm. (Nguyen, 2005). Perineural invasion is difficult to 
quantify but there is some suggestion and it seems logical that increasing diameter of the 
involved nerve is associated with increased risk. (Jambusaria-Pahlajani, 2010).  
3.4 Histology 
The histologic appearance of SCC will show keratinocyte hyperplasia and anaplasia, often 
with areas of dyskeratosis where keratin pearls will appear randomly in islands of 
squamous cells (See Figure 3b). Poorly-differentiated SCCs will lose the keratin production 
with a corresponding increase in the anaplastic appearance of the squamous cells. The 
pathologist may characterize the SCC as “well,” “moderately,” or “poorly” differentiated 
but often parses the terminology for intermediate states such as “well to moderately” or 
“moderate to poorly” differentiated. The poorly-differentiated SCCs warrant a high degree 
of vigilance since up to 17% of such tumors have been reported to metastasize compared to 
well-differentiated tumors with an estimated 0.6% risk. (Breuninger et al., 1990).  
 
Fig. 3b. Histology of squamous cell carcinoma 
3.5 Treatment options 
When considering treatment options for SCC, approaches other than RT can be divided into 
three groups: topical therapies, destructive therapies, and surgical resection with margin 
control. The selection of a treatment modality will be greatly influenced by a number of 
variables that contribute to the physician’s assessment of the perceived risk of metastases, 
the cosmetic and functional consequence of the treatment, and the general health status of 
the patient. RT can be effective as both a primary treatment as well as an adjuvant therapy 
for high-risk tumors.  
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When it comes to selecting RT for primary tumors, the first question to address is whether 
surgical excision with margin control is either feasible or practical since MMS has the highest 
reported cure rates for SCC compared to all other modalities. However, like all treatments for 
SCC, MMS cure rates begin to drop with increasing aggressive features such as tumor size, 
differentiation, discontinuity, perineural invasion, and a history of recurrence(s). Meta-analysis 
shows that MMS has 5-year recurrence rates for primary cutaneous SCC of 3.1% vs. 7.9% for 
other treatment options including CE, RT, and surgical excision. (Rowe et al., 1992). When it 
comes to high-risk tumors, MMS trumps other modalities as well for SCC of the lip, 2.3% 
(Mohs) vs. 10.5% (non-Mohs), on the ear, 5.3% (Mohs) vs. 18.7% (non-Mohs), and recurrent 
SCC 10.0% (Mohs) vs. 23.3% (non-Mohs). (Rowe et al., 1992).  
In the clinical setting, circumstances arise where either MMS or surgical excision is simply 
not realistic and RT offers a reasonable alternative. The approximate overall 5-year cure rate 
for RT for primary SCC is on the order of 90%. (Rowe et al., 1992). There is great hesitancy 
on the part of many dermatologists to refer patients younger than 60 years of age due to 
perceptions of long-term cosmetic consequences of RT as previously mentioned, coupled 
with fears of increased risk of future malignancy in the treatment site. Although RT is 
associated with a statistically increased risk of secondary malignancies, one has to judge the 
clinical significance of the elevated risk before discounting RT in younger patients. Meadows 
et al. evaluated the risk of secondary neoplasms amongst survivors of childhood cancer 
from a large, United States, population-based registry. (Meadows et al., 2009). With 30 year 
follow-up, they demonstrated that the cumulative incidence of non-melanoma skin cancers 
in children who received RT was 4%, whereas the incidence in non-irradiated patients was 
1%. So although the relative risk is high, the absolute excess risk for these non-lethal cancers 
is arguably low. With regard to other secondary malignancies, the cumulative incidence of 
secondary cancers over 30 years was 6% in the irradiated children, and 3% in the non-
irradiated children.  
The discussion of the treatment for SCC in the NCCN website is very candid about diversity 
of opinions about the role of RT for primary SCC across academic institutions, and more 
specifically between surgeons and radiation oncologists, stating that the radiation 
oncologists on the panel wanted to suggest that RT be considered as a first line therapy, 
whereas the surgeons did not. (NCCNN, 2011). The discussion was based on a large review 
of published data. (Avila et al., 1977; Collin, 1976; Fischbach et al., 1980; Fitzpatrick, 1995;  
Johnson et al., 1992; Lovett et al., 1990; Martin et al., 1970; Mazeron et al., 1988; Mendenhall 
et al., 1987; Petrovich et al., 1987a, 1987b, 1988; Rowe et al., 1989a, 1989b, 1992; Silverman et 
al; 1991, 1992; Stoll et al, 1964; Traenkle et al., 1962).  
3.5.1 RT as primary therapy for SCC 
The National Comprehensive Cancer Network published guidelines for RT for primary SCC 
are reprinted with permission in Table 1. Within these guidelines are specific dosing 
recommendations for primary SCC and BCC that are stratified by tumors < 2 cm and tumors ≥ 
2 cm. In general, control rates for SCC primarily treated with RT are excellent, but slightly less 
effective than for BCC. In a report by (Solon et al., 1997) the four-year control rate was 96% 
(426/444) for BCC and 92% (144/156) for SCC with RT as primary therapy. As is the case for 
BCC, size influences local control rates as demonstrated by (Lovett et al., 1990): control rates for 
tumors less than 1 cm were 97% (86/89) for BCC vs 91% (21/23) for SCC; tumors 1-5 cm in size 
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had control rates of 87% (116/133) for BCC vs 76% (39/51) for SCC; and for lesions larger than 
5 cm local control was 87% (13/15) for BCC vs 56% (9/16) for SCC.  
Anatomic site considerations are critical in selecting therapy for primary SCC. MMS has 
excellent cure rates but is very morbid at specific anatomic sites with the consequence of 
posing difficult and complicated reconstructive challenges. For instance, SCC of the eyelids 
can often be treated with RT with high cure rates thus avoiding difficult staged surgical 
repairs. Also, tumors around the lacrimal system treated with RT can preserve the drainage 
system (JS, 2005) which is often compromised by reconstructive surgery. It was previously 
thought that lesions over cartilage, such as the ear, should not be treated with RT due to the 
risk of chondronecrosis, but it is now known that such sites can be safely treated with 
fractionated RT. (JS, 2005).  
Verrucous carcinoma is particularly radiosensitive and RT can reasonably be considered as 
a first line therapy. Anogenital SCC is not uncommon, and surgical approaches can be very 
morbid leading to permanent loss of function and disfigurement. For anal SCC, the standard 
of care for most T1 and all T2 lesions and above is definitive combined chemoradiotherapy, 
with surgery reserved only for recurrences. (Bartelink et al., 1997; Flam et al., 1996; 
UKCCCR, 1996). This therapy results in equivalent cure rates to radical surgery, but offers 
functional organ preservation.  
The medical community has embraced chemoradiotherapy as the gold-standard curative-
intent treatment for most advanced squamous cell carcinomas of the head and neck, 
esophagus, uterine-cervix, and anus, with the goal of functional organ preservation. 
However, for the more rare entity of penile cancer, surgery remains the most commonly 
performed treatment. Surgical approaches to SCC of the penis frequently result in 
distortions of the urethra with consequential disruptions of urine flow direction. Partial or 
complete penectomies are extremely morbid procedures often with devastating emotional 
and psychological consequences for the patient. (Sarin et al., 1997). The authors have a series 
of successfully treated SCC of the penis. As one example, a 49 year old man presented with 
verrucous carcinoma staged as T1a,N2,M0 (stage IIIB). He presented with conventional 
condylomas on the base of the penis with a cauliflower morphology, while on the penile 
shaft there were verrucous plaques with hyperkeratosis and fissuring (See Figure 4). 
Penectomy and radical inguinal surgery had been recommended, but the patient elected to 
undergo an organ-sparing approach. He was treated with a regimen that would be 
considered “standard” for an anal SCC: 5580 cGy to the penis, 4500 cGy to the inguinal and 
pelvic nodes using an intensity-modulated radiotherapy technique. RT was given with 
concurrent weekly cisplatinum at 40 mg/m2.  
RT can also be used for SCC that involves the glans penis and encroaches on or involves the 
urethra where surgery can cause permanent disfiguration. Because penile cancer is a rare 
entity, no prospectively performed trials with RT exist. However, numerous retrospective 
studies using interstitial brachytherapy, external beam radiotherapy, or combinations have 
been reported and are summarized in Table 2. (Sarin et al., 1997) Of note, these studies did 
not combine chemotherapy with RT and demonstrate local control rates in the 57% to 85% 
range with RT alone with excellent functional and cosmetic results. It is important to note 
that the local failures were successfully salvaged with RT, leading to ultimate control rates 
of 90% to 97%. The most common functional deficit reported after RT is urethral stricture, 
reported in 9-41% of subjects. (Sarin, 2002).  
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Fig. 4. Verrucous carcinoma of the penis, pre- and post- treatment 
 
Table 2. Radiotherapy for penile cancer (Data compiled in: Treatment Options for Urological 
Cancer, 2002) 
3.5.2 RT as adjuvant therapy for SCC 
For patients that have had the SCC removed surgically but are thought to be at high risk for 
local recurrence due to perineural invasion or aggressive histologic patterns, post-operative 
adjuvant RT should be considered. This is particularly true where perineural invasion is 
present despite negative margins on histology, as the patient is known to have a substantial 
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increased risk of local recurrence (Nyguyen, 2005). (See Table 1). RT for SCC showed 5-year 
actuarial local control of 0.54 for primary SCC, 0.0 for recurrent SCC, and 0.42 for nodal 
metastases. (Shim & Wilder, 1991).  
3.5.3 RT for regional lymph node involvement 
Regional disease includes SCC that has spread to regional lymph node basins and is divided 
into two treatment groups: those patients who have undergone completion lymph node 
dissection and are deemed at high risk for local recurrence, and those patients who did not. 
The NCCN guidelines committee suggests that all doses be delivered at 2 Gy per fraction 
using the shrinking field technique. This means the highest-risk areas should be prescribed 
the dose specified in Table 3, but lower doses may be prescribed for elective nodal region at 
less of a risk for relapse. For tumors after lymph node dissection, patients are stratified to 
those having extracapsular extension (ECE) and those who do not, and dosages are stratified 
by site: head and neck vs. axilla and groin (See Table 3). 
 
Table 3. Dose Recommendations for Squamous Cell Carcinoma: Regional Disease (2 Gy per 
fraction with shrinking field technique). Used by permission of the National Comprehensive 
Cancer Network 
Although the above nodal dose guidelines represent level II consensus guidelines from the 
NCCN skin panel, it is noteworthy that the doses used to control nodal metastases in anal 
squamous cell cancers are lower (usually in the 45Gy to 56Gy range) when given in the 
context of chemotherapy. This could be due to the potent radiosensitizing effect of 
chemotherapy or an intrinsic radiosensitivity of anal squamous cell primaries relative to 
other locations. 
4. Melanoma  
Melanoma is the third most common skin cancer but is responsible for the majority of skin 
cancer deaths in the United States. The majority of melanomas present either as an unusual 
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appearing nevus relative to the other nevi on the body, or occur as a change in an existing 
nevus. Melanoma begins with the melanocyte, the pigment-producing cell of the epidermis 
which is derived from the neural crest during embryology (See Figure 2). The virulence of 
melanoma may be in part related to its origin, where it appears on the stage very early 
during embryogenesis and may have the cassette of genetic capabilities for migration not as 
common in basal cells and squamous cells that appear much later as the fetus develops. For 
whatever reason, melanoma has a high propensity for metastasis which is directly related to 
the depth of invasion measured in millimeters from the granular layer to the deepest part of 
the tumor by a calibrated ocular micrometer, and is referred to as the Breslow depth.( 
Breslow, 1970). For example, a melanoma with a Breslow depth less than 1 millimeter 
without other adverse features predicts a 5-year survival of about 95%, whereas a melanoma 
4 millimeters in depth without other adverse features has an associated survival of about 
65%. If ulceration is present in the primary tumor, survival for a 4 millimeter melanoma 
drops to about 50% at 5 years. (Balch et al., 2009).  
4.1 Epidemiology 
It is estimated that in 2010 there were 68,130 new cases of invasive melanoma in the U.S., 
with 8700 deaths (Jemal et al., 2010). The incidence of melanoma continues to rise as 
demonstrated by the Surveillance, Epidemiology and End Results (SEER) data, which has 
shown an increase in incidence in the United States from 6.7 cases per 100,000 in 1973 to 20.4 
cases per 100,000 in 1996 in males, and from 5.9 cases per 100,000 to 14.3 cases per 100,000 
cases in females. (Berwick, 2003; Surveillance, 2002). Although melanoma can occur in black 
patients, it is much more common in Caucasian patients with the highest rates of incidence 
in Australia (40.5/100,000), New Zealand (36.7/100,000), Norway (14.1/100,000) and the 
United State (13.3/100,000) for males. (Berwick, 2003; Ferlay et al., 2001).  
4.2 Etiology 
Melanoma appears to be a consequence of both genetic factors and environmental factors, in 
particular exposure to ultraviolet light. Well-known risk factors for melanoma include a 
personal or family history of melanoma, UV exposure, childhood sunburns, a high number of 
nevi, fair skin, blue eyes, easy freckling, higher socioeconomic status, and living at equatorial 
latitudes, to name a few. (Nestle, 2003). The majority of melanoma cases are spontaneous, but 
it is estimated that 6% to 14% of melanomas occur in family groups. (Ang et al., 1998). The 
gene most frequently involved in melanoma resides on chromosome 9p21 and is known as 
CDKN2A, whose gene product (p16) acts a tumor suppressor. (Pollock et al., 2003).  
4.3 Clinical presentation 
Melanoma can be roughly divided into various categories that have differing biological and 
genetic characteristics with varying degrees of causation by sun-exposure. For example, 
most melanomas appear on intermittently-exposed sites such as the torso. Other subtypes 
occur in chronically-exposed sites such as the head and neck, non-sun-exposed sites such as 
the palms, soles, genital/mucosal surfaces and ocular melanoma form their own entity. 
(Whiteman, et al., 2011).  
In general, melanoma will present as a pigmented lesion that visibly changes over time, 
usually in terms of size and/or color (See Figure 5a). A very useful feature termed the “ugly 
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duckling” sign (Grob & Bonerandi, 1998) connotes the disparity in the appearance of the 
melanoma compared to surrounding nevi. We have found the “ugly duckling” sign to be of 
particular effectiveness in identifying melanomas in our high-risk patient group in our 
mole-mapping clinic at our institution, where total body photography is used to track nevi 
longitudinally for any signs of change that might herald malignant transformation. 
(Goodson et al., 2010).  
 
Fig. 5a. Superficial spreading melanoma with border irregularity and color variation. 
4.4 Histology 
Entire book chapters and even books have been dedicated to the problem of reproducibly 
making the distinction between melanoma and severely atypical nevi that are not melanoma 
under the light microscope. For the purposes of this chapter, the hallmark histologic features 
of melanoma include the proliferation of atypical melanocytes with lack of maturation of the 
melanocytes with depth, (See Figure 5b.) The presence of ulceration, mitotic figures, and 
angiolymphatic invasion are negative prognostic features. (Nestle, 2003).  
 
Fig. 5b. Histology of superficial spreading melanoma 
4.5 Treatment 
Melanoma is, by and large, considered a surgical disease. The role of RT for melanoma can 
be summarized as the occasional use as primary treatment for lentigo maligna (LM) or 
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unresectable primary tumors and in the adjuvant setting to improve local control or 
palliation. 
4.5.1 Radiation as first-line therapy for melanoma 
Lentigo maligna (LM) is a subtype of melanoma that occurs in chronically sun-exposed sites, 
usually on the head and neck, and is subdivided into lentigo maligna (LM), which is an in 
situ tumor, and lentigo maligna melanoma (LMM) which connotes histologic invasion. 
When invasion is present, the recommended treatment is surgical resection. (NCPGION, 
2011). However, in situ tumors pose no immediate threat of metastases to the patient and 
are treated to prevent the future potential for invasion. The actual risk of invasion is 
unknown but has been predicted to occur at a rate of 2.2%at 45 years and 4.7% at 65 years. 
(Weinstock & Sober, 1987). In such cases, RT can be considered as a primary therapy for LM, 
because surgical excisions commonly result in very large defects with significant associated 
morbidity. (Johnson et al., 1997). When RT is used as primary therapy for LM (Grenz rays or 
soft X-rays using the Miesher technique), the cure rates range from 86 to 95%. (Farshad et al., 
2002; Schmid-Wendtner et al., 2000; Tsang et al., 1994). The largest published study to date 
included 150 patients with both LM and LMM and a mean follow-up of 8 years with a 
complete response rate of 93%. (Farshad et al., 2002). For LM, definitive RT achieved a crude 
local control rate of 95%, with a mean time to recurrence of 45.6 months. Four of the five 
recurrences were at the edge of the radiation field, so the authors recommended targeting a 
margin of at least 10 mm around the visible lesion. (Farshad et al., 2002).  
4.5.2 RT in the adjuvant setting for local or regional disease 
Adjuvant RT is recommended for consideration in the NCCN guidelines under several 
circumstances: primary disease at risk for local recurrence, regional disease, and metastatic 
disease. (NCPGiON, 2011). As for primary disease, adjuvant radiation is often considered 
for the desmoplastic subtype of melanoma (DNM), a spindle cell variant of melanoma that 
is frequently associated with perineural invasion and is prone to local recurrences. 
(Vongtama et al., 2003). RT can be considered post-operatively when extensive 
neurotropism is present, since this will put the patient at an increased risk of a local 
recurrence (See Table 4). (Chen et al., 2006). RT was also recommended for patients with 
inadequate margins, which occurred predominately in the head and neck region in this 
series.    
Regional disease includes large primary tumors > 3 centimeters in diameter as well as those 
cases where there are in transit or satellite metastases around the primary tumor where it is 
not practical to resect them with the primary tumor (See Table 4). However, even with 
radiation, patients with satellitosis are at risk for a recurrence in the radiated field. (Chang et 
al., 2006). Dosing must be tailored to specific sites and sizes of radiation fields. The head and 
neck area can be treated with orthovoltage or low-energy electrons with bolus in doses 
ranging from 24 to 36 Gy in four to six fractions. The larger the area, > 50 cm2, the greater 
the need for more fractions, especially on the distal lower extremity. It has been 
recommended that a large surface on the trunk can tolerate 36 Gy in 12 fractions, however, a 
similar sized field on the lower limbs should be treated with 50 Gy in 25 fractions over 5 
weeks. (Ainslie & McKay, 2003). 
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PRIMARY DISEASE 
 Adjuvant treatment for selected patients with desmoplastic melanoma with extensive
neurotropism 
REGIONAL DISEASE 
 Extracapsular extension 
 ≥4 involved nodes 
 Size ≥ 3 cm 
 Cervical **> Axillary > Inguinal Location 
 Recurrent disease after prior complete nodal dissection 
**For cervical nodes, consider RT if >2 nodes involved or nodes > 2cm in size 
 
METASTATIC DISEASE 
 Brain metastases (see NCCN Central Nervous System Cancers Guidelines) 
- Definitive or palliative stereotactic radiosurgery and/or whole brain radiation 
- Adjuvant radiation following resection of brain metastases 
 Other symptomatic or potentially symptomatic soft tissue and/or bone metastases 
Table 4. Principles of Radiation Therapy for Melanoma (Reprinted by permission of the 
National Comprehensive Cancer Network) 
For nodal melanoma that has been completely resected, adjuvant RT is considered where a 
high risk of local recurrence is anticipated (see Table 4). (NCPGiON, 2011). There are no 
published multi-center trials for RT in this setting, and published data are from single 
institutions. Most studies demonstrate improved regional control compared to surgery 
alone. (Ang et al., 1994; Burmeister et al., 1995; Corry et al., 1999; O’Brien et al., 1997; Stevens 
et al., 2000; Strom & Ross, 1995). The largest retrospective review investigating the role of RT 
included 615 patients meeting high-risk criteria for relapse. (Agrawal et al., 2009). At a 
median follow-up of 5 years, regional recurrence occurred in only 10.2% of the radiated 
patients versus 40.6% of the non-radiated patients. Of note, RT significantly increased 
treatment-related morbidity (5-year rate of 20% versus 13%, p=0.004), particularly with 
regards to lymphedema. The consensus opinion appears to be that overall survival is not 
greatly improved with adjuvant RT because four randomized trials involving complete 
surgical removal of subclinical lymph node involvement with elective lymph node 
dissections did not significantly improve survival. (Ainslie & McKay, 2003; Balch et al., 2000; 
Cascinelli et al., 1998; Sim et al., 1986; Veronesi et al., 1982). Retrospective data has not 
shown one regimen is more efficacious or safe than another, but delivering radiation over a 
longer time period might decrease the risk of side effects. (Chang et al., 2006). Several 
published series warn about the concomitant use of RT and interferon-alpha where 
increased regional toxicity has been observed. (Buckner et al., 2001; Damle et al., 1999; 
Hazard et al., 2002; Holsti et al., 1987; Stock et al. 1997).  
When local, regional, or metastatic melanoma is not completely resected or is deemed 
unresectable, palliative RT should be considered. Although randomized trials have not 
shown any superiority of hypofractionated regimens over standard fractionation, a 
biologically effective dose >39 Gy10 (i.e. a regimen stronger than 30 Gy in 10 fractions) is 
recommended (See Table 4). (Ainslie & McKay, 2003; Olivier et al., 2007; Overgaard et al. 
1985; Sause et al., 1991). Radiation effectively improves patient quality of life, as significant 
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symptom relief is achieved for 68% to 84% of patients. (Konefal et al., 1988; Olivier et al., 
2007). Reports for clinical complete response (CR) rates range from 17 to 69%, with 49 to 
97% achieving either a partial response (PR) or CR. (Overgaard et al., 1985; Sause et al., 1991; 
Seegenschmiedt et al., 1999).  
4.5.3 RT in the setting of metastatic disease  
As for metastatic disease, RT is recommended for brain metastases as either definitive 
stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT) for palliation. RT is 
also considered post-operatively in cases where a brain metastasis has either been resected 
or treated with SRS. (Fogarty et al., 2011). For patients with multiple metastatic melanoma 
lesions in the brain, WBRT is the most frequently utilized form of palliation. In a summary 
of a large number of series, WBRT provided symptomatic improvement in over two-thirds 
of patients, however, the medial survival is only 3.5 months. (Morton et al., 2003). A 
cautionary note is important to consider in the rare cases where patients have prolonged 
survival and can experience brain atrophy and consequential dementia. Striking functional 
decline was documented in 30% of women undergoing prophylactic brain irradiation in 
metastatic breast cancer. (Huang et al., 2009). In another study, brain atrophy developed in 
30% of 92 patients undergoing WBRT, although the authors state that this was not 
necessarily accompanied by decreases in mini-mental status examination scores. (Shibamoto 
et al., 2008). It should be noted that over 90% of patients with brain metastases have been 
found to have some level of neurocognitive dysfunction before radiation. (Meyers et al., 
2004). Although long-term survival is unlikely following WBRT for melanoma, it is 
advisable to inform patients and family members of the risk for post-treatment dementia.  
For solitary metastatic lesions in the brain, surgical resection (potentially followed by 
radiation) or SRS should be considered. In two radomized trials for solitary melanoma 
metastases in the brain, surgical resection followed by WBRT led to better palliation and 
prolonged disease-free survival than surgery alone. However, overall survival was only 
increased in one of the two studies (18-month vs. 6-month medial survival; P = 0.002). 
(Hagen et al., 1990; Skibber et al., 1996).  
SRS is becoming an increasingly-used alternative to craniotomy/surgical resection in 
patients with a small number (generally ≤ 4) of brain metastases, each measuring ≤ 4 cm. 
(Breneman et al., 1997; Chen et al., 2000; Samlowski et al., 2007). SRS may be a way to 
quickly address brain metastases  to allow for intracranial control, perhaps buying time 
until more systemic options become available. In general, SRS alone or followed by WBRT 
yield results similar to surgical resection followed by WBRT. Again, the addition of WBRT 
after surgery or SRS improves disease-free survival but not necessarily overall survival. 
(Bafaloukos & Gogas, 2004).  
5. Merkel cell carcinoma 
Also known as primary neuroendocrine carcinoma of the skin, Merkel cell carcinoma (MCC) 
has the dubious distinction of being the most deadly of the skin cancers, including 
melanoma. Despite its virulence, MCC has not achieved the notoriety of melanoma due to 
its rarity.  
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5.1 Epidemiology 
In the United States, MCC accounts for much less than 1% of all cutaneous malignancies and 
is estimated to occur at 0.24 tumors per 100,000 person-years compared to 17.0 tumors per 
100,000 person-years for melanoma. (Agelli & Clegg, 2003). Overall survival rates are 
estimated to be 87% (1 year) and 49% (5 years) and a cause-specific survival rate of 62% at 
five years. (Lewis et al., 2006).  
5.2 Etiology 
The Merkel cell polyoma virus is detected in 43% to 100% of MCC tissue (Feng et al., 2008; 
Rollison et al., 2010), but its exact role in the pathogenesis of MCC remains to be sorted out. 
(Group, 2009). Because MCC tends to occur in a distribution similar to BCC and SCC, 
ultraviolet light has been suspected as playing a causative role, perhaps in conjuction with 
polyoma virus infection, but the exact etiology remains elusive.  
5.3 Clinical presentation 
MCC does not have a distinct and characteristic clinical presentation and is frequently 
mistaken for both benign and malignant neoplasms, but does have a predilection for sun-
exposed sites on the head and neck, sun-exposed extremities and is most commonly seen in 
elderly Caucasians (See Figure 6a). Clinical signs of regional lymph node involvement is 
seen in 11-15%, while 50-70% of patients will eventually develop regional nodal metastases. 
(Hitchcock et al., 1988). Local recurrence rates are very high: 25-30%. Up to 50% of patients 
develop distant metastases with the most common sites being the liver, bone, brain, lung, 
skin, and distant lymph nodes. (Akhtar et al., 2000; Gillenwater et al., 2001; Medina-Franco 
et al., 2001; Taylor & Heilman, 2005).  
 
Fig. 6a. Merkel cell carcinoma, with bunch biopsy site in center of tumor 
The most important prognostic feature of MCC is the stage followed by tumor size. (Akhtar 
et al., 2000; Allen et al., 1999; Haag et al., 1995; Kokoska et al., 1997; Medina-Franco et al., 
2001; Ott et al., 1999; Ratner et al., 1993; Skelton et al., 1997). The American Joint Committee 
on Cancer (AJCC) staging system divides the presentation of MCC into local, regional, and 
disseminated disease. (Edge et al., 2009). 60%-70% of patients present with local disease only 
(Stage I) and have with an estimated 3-year survival of 55-73%, while up to 40% of patients 
present with regional node involvement (Stage II) with a 33% 3-year survival estimate. 
(Yiengpruksawan et al., 1991).  
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5.4 Histology 
The histopathology of MCC may mimic other types of malignancies, particularly basal cell 
carcinoma. Under light microscopy, the appearance is one of monotonous aggregates of 
small basophilic cells that are closely packed with a large nuclear:cytoplasmic ratio (See 
Figure 6b). A high mitotic rate and vesicular nuclei are common. The neoplasm is mostly 
dermal and is usually separated from the epidermis by a thin layer of uninvolved dermis 
called the “Grenz zone.” Histologically, the closest simulant to MCC is metastatic small cell 
carcinoma of the lung. The distinction between those two diagnoses can usually be made 
with immunohistochemistry, since MCC reacts with the immunostain for cytokeratin 20 
(CK20) in 89-100% of tumors but does not react with thyroid transcription factor 1(TTF-1) 
which is expressed in small cell lung cancer but not MCC. (Cheuk et al., 2001; Hanly et al., 
2000; Scott & Helm, 1999).  
 
Fig. 6b. Histology of Merkel cell carcinoma 
5.5 Treatment 
Like melanoma, MCC is a disease best treated surgically. The National Comprehensive 
Cancer Network™ (NCCN) panel has acknowledged substantial variability in treatment 
recommendations among physicians representing multiple institutions across the United 
States, therefore, the treatment recommendations by the NCCN are broad to include 
disparate attitudes between institutions hampered by the lack of randomized controlled 
studies to draw upon. (NCPGiON, 2011). In general, a wide local excision is recommended 
for the primary site with the option of adding a sentinel lymph node biopsy. Postoperative 
radiation to the primary site is routinely performed at some institutions, whereas others add 
RT only if the surgical margins are close or positive. The same philosophy applies to 
regional lymph node basins where some institutions will routinely irradiate regional lymph 
node basins regardless of sentinel lymph node status, while others reserve postoperative RT 
for basins with positive nodes, and in some cases, only if the nodes demonstrated 
extracapsular spread.  
The difficulty in making firm treatment recommendations for RT sits firmly in the paucity of 
prospective randomized data from which to make informed clinical decisions. Despite the fact 
that the benefits of RT in MCC are mixed in the literature, there is published evidence that 
postoperative radiation can help to minimize locoregional recurrences but not necessarily 
improve overall survival. A meta-analysis compared surgery alone compared to surgery 
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followed by RT to the surgical site showing a lower risk of local and regional recurrences but a 
difference in overall survival did not reach statistical significance. (Lewis et al., 2006). In a 
series of 82 patients, both relapse-free survival and overall survival were improved with RT to 
the primary site or the regional lymph node basins (Jabbour et al., 2007), therefore, the NCCN 
panel includes RT as an option for all stages of MCC. Further support for adjuvant RT comes 
from a SEER analysis of 1,665 patients, which showed RT was associated with improved 
survival for all size tumors, especially for those >2 cm. (Mojica et al., 2007).  
There are occasions where RT is an acceptable first line therapy for primary tumors, 
particularly when the tumors are large, have satellite metastases, deemed unresectable, or the 
patient is a poor surgical candidate. Because MCC tends to occur in an elderly patient cohort, 
surgical morbidity is often a significant consideration when designing a treatment strategy. In 
a retrospective series of 43 patients, RT was used as monotherapy and had a reported in-field 
tumor control rate of 75%. (Veness et al., 2010). Additionally, radiation may be useful for 
palliation when surgical resection is not feasible for either primary or secondary lesions. 
 
Table 5. Dose Recommendations for Merkel Cell Carcinoma (2 Gy per fraction with 
shrinking field technique) 
Table 5 with recommended dosages for RT for MCC is reprinted by the permission of the 
National Comprehensive Cancer Network™ with the following qualifying comments. When 
MCC on the extremities and torso has been treated with wide local excision (WLE) with 
negative margins and negative sentinel lymph node biopsy (SLNB), RT is usually reserved 
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for the primary site only (but not given at all institutions). If a SLNB is not performed, RT to 
the nodal basins can be considered. For head and neck MCC, the risk of falsely negative 
SLNB is higher and two scenarios may exist: first, if the SLNB is negative, consideration can 
be given to irradiate the primary site +/- the nodal beds or observe; second, if the WLE is 
performed without SLNB, consideration should be given to irradiate the primary site +/- 
nodal beds with the in-transit lymphatics if feasible. 
As for the authors, the decisions made regarding the use of RT as either a primary therapy 
or adjunctive therapy for resected MCC occur after presentation of each individual case in a 
multidisciplinary tumor conference setting. The multidisciplinary conference has the 
advantage of including the input of the radiation oncologists, pathologists, surgeons, 
medical oncologists, and dermatologists. The details of each specific case with regards to 
staging, tumor histology characteristics, general state of health of the patient, etc. are all 
factored into tailoring a treatment algorithm appropriate for a given patient and clinical 
scenario.  
6. Cutaneous lymphoma 
The cutaneous lymphomas are a subtype of extra-nodal non-Hodgkins lymphomas that are 
generally divided into three categories: cutaneous T-cell lymphomas, cutaneous B-cell 
lymphomas, and the natural killer cell (NK cell) lymphomas. As a group, the cutaneous 
lymphomas are considered as skin-associated lymphoid tissue (SALT) lymphomas. 
Although there are histologic correlates with the systemic lymphomas, the distinct clinical 
characteristics and clinical courses of the skin lymphomas requires that the clinician 
consider them as distinct entities when considering treatment options.  
6.1 Cutaneous T-cell lymphoma  
When most clinicians hear the term “cutaneous T-cell lymphoma” (CTCL), they are likely to 
bring images to mind of the two most well-known variants: mycosis fungoides (MF) and 
Sézary syndrome (SS). There are, in fact, a fascinating myriad of CTCL subtypes including MF, 
SS, anaplastic large cell lymphoma, subcutaneous panniculitis-like CTCL, granulomatous slack 
skin, and peripheral T-cell lymphoma to name a few of the most frequently-encountered 
variants. Both focal electron beam therapy and total body electron beam therapy can greatly 
reduce morbidity and may provide complete cures in many cases.  
6.1.1 History 
The term “mycosis fungoides” is an unfortunate appellation that has been a source of 
confusion since the term was coined by the French physician Alibert, who first described the 
condition in 1806 in a single patient with tumor stage MF presenting with large fleshy 
protuberances on the head and neck that indeed resembled mushrooms, hence the name, 
“mycosis fungoides.” (JLM, 1806). The report occurred long before fungus was known to 
cause disease in the skin and was rather a descriptive term that continues to confuse both 
patients and physicians alike, who naturally associate the diagnosis with an underlying 
fungal infection. MF is an extra-nodal cutaneous lymphoma predominantly comprised of 
CD4+ T-cells. 
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The second most well-known variant is Sézary syndrome (SS), which can be thought of as 
the leukemic variant of MF where there are a high number of circulating enlarged malignant 
lymphocytes called “Sézary cells,” as described by Sézary in 1936 in a patient with what 
came to be known as the classic triad of erythroderma (globally inflamed red skin), 
lymphadenopathy, and more than 10% of the circulating white blood cells have a Sézary cell  
morphology under light microscopy. (Sezary, 1938). The principles of radiotherapy will be 
similar for MF, SS, and the various subgroups, therefore, MF and SS will be used as 
representative diseases for modeling therapy in this chapter. 
6.1.2 Epidemiology 
In the United States, CTCL is considered a rare disorder. A review data from 13 population-
based cancer registries of the Surveillance, Epidemiology, and End Results (SEER) Program 
of the National Cancer Institute was reviewed from 1973 to 2002 and an incidence of 6.4 
cases per million was observed. (Criscione & Weinstock, 2007). An increasing incidence was 
observed over that observation period but the reason for the increased incidence is 
unknown. CTCL is most certainly underreported. The majority of cases of MF are low-grade 
and are treated locally by dermatologists and not referred to cancer treatment centers and 
consequently, not entered into tumor registries. Also, many cases of early stage MF are not 
actually diagnosed accurately since MF can easily simulate either psoriasis or eczema and 
confirming biopsies are never performed, so the diagnosis is never entered into tumor 
registries. 
6.1.3 Clinical presentation 
MF has a distinct clinical presentation that classically begins as erythematous patches that 
can eventually progress to thicker plaques, and then to raised tumors on the skin (See Figure 
7a). This progressive nature of the skin involvement is captured in the staging schema with 
T1 being patches and plaques covering less than 10% of the total skin surface, T2 for > 10% 
of the surface, T3 for tumors, and T4 for erythroderma or red inflamed skin globally 
distributed. The distribution of MF lesions is, in general, very reproducible with the patches 
predominantly located in sun-protected areas in a “bathing-suit” distribution. This implies 
involvement of the axilla, mid-axillary line, torso, buttocks, and groins. The fact that 
ultraviolet light is frequently very effective in treating MF may explain why the disease is 
much less frequently observed in sun-exposed sites. For patch-stage patients, the lesions are 
curiously positioned in the middle ground between psoriasis plaques and patches of atopic 
dermatitis (eczema), where the former are very well-demarcated while the later have much 
less defined borders.  
SS presents with an entirely different clinical picture where the patients present with 
widespread erythema and scaling, and frequently have difficulty maintaining a 
comfortable body temperature due to the massive loss of heat through the dilated 
capillaries diffusely in the skin. Patients with SS frequently have severe pruritus 
accompanied by fissures and erosions that often get infected, and indeed the main cause 
of death for both MF and SS is sepsis from a skin source. SS patients classically present 
with palpable lymphadenopathy. 
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Fig. 7a. Cutaneous T-cell lymphoma (mycosis fungoides) 
6.1.4 Histology 
The biopsy of classic early stage MF has the distinct feature of swarms of atypical 
lymphocytes in the upper dermis that home to the epidermis like moths to a street lamp 
(epidermotropism). The epidermis is peppered with atypical lymphocytes occurring singly 
and in clusters of T-cell aggregates eponymously called “Pautrier microabscess” (See Figure 
7b). (LM, 1937). Problematically, MF is a slowly evolving disease and it may take many 
years before a skin biopsy displays distinctive diagnostic features. In such ambiguous cases, 
skin specimens are submitted for clonality testing by looking for overexpression of a 
singular T-cell receptor on the surface of the CD4+ cells. As the disease progresses from 
patches and plaques to tumors, the epidermotropism is lost and densely packed aggregates 
of atypical lymphocytes are seen occupying the superficial and deep dermis without 
epidermal involvement.  
 
Fig. 7b. Histology of cutaneous T-cell lymphoma, mycosis fungoides subtype 
The histology of SS is even more problematic since the classic features of MF are only seen 
about half of the time, whereas the remaining cases may be impossible for the 
dermatopathologist to distinguish from generic “dermatitis” where the influx of 
lymphocytes is so extreme that the distinguishing features of the Pautrier microabscesses are 
lost. In such cases, flow cytometry of the peripheral blood can be very helpful and cell 
sorting easily detects an aberrant overexpression of a T-cell clone.  
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6.1.5 Staging 
In general terms, T1 disease includes patients with less than 10% of the skin involved and 
the five-year survival is not statistically different than that for the control population. (Kim 
et al., 1996). Patients with T2 disease (> 10% of the skin surface involved) do have an 
increased mortality with 15% eventually dying from their disease. (Kim et al., 1999). 
Approximately half of all patients with T3 disease (skin tumors) or T4 disease 
(erythroderma) die of their disease. (Kim et al., 2003).  
6.1.6 Treatment  
The majority of patients presenting with MF are treated with skin-based therapies, most 
frequently ultraviolet light in the form of narrow band UVB or PUVA which is UVA 
combined with the orally ingested photosensitizer “psoralens” (psoralens + UVA = PUVA). 
Topical agents include topical chemotherapeutic agents such as nitrogen mustard and 
carmustine, and a topical retinoid, bexarotene. When these skin-based topical therapies are 
ineffective, systemic therapies that can be considered include interferon –alpha 2b given as 
subcutaneous injections (Olsen & Bunn, 1995) and is often combined with a skin-based 
therapy such as ultraviolet light. Another alternative is oral bexarotene (Olsen & Bunn, 
1995), which can also be combined with light therapy. Newer agents include the histone 
deacetylase inhibitors vorinostat (oral) (Kavanaugh et al., 2010) or romidepsin (intravenous). 
(Bertino & Otterson, 2011). Denileukin difititox is a fusion protein of interleukin-2 with a 
diphtheria toxin moiety that acts as a Trojan horse of sorts. The fusion protein is bound to 
the surface of the T-cell by its IL-2 receptor and the drug is internalized and the diphtheria 
toxin provokes apoptosis. (Duvic & Cather, 2000).  
6.1.7 Radiation therapy for CTCL 
Radiation therapy plays a critical role in the treatment of MF and is considered in three 
scenarios: curative treatment for uni- or paucy lesional MF, intent to achieve a complete 
response with total skin electron beam therapy (TSEBT), or local palliation with external 
beam radiation therapy (EBRT).  
MF is radiosensitive compared to other skin cancers and doses as low as 2000-3000 cGy can 
yield high rates of durable remissions. For localized cases of stage I MF, electron beam is the 
most common radiotherapeutic modality, however, kilovoltage X-rays also have rapid dose 
fall off and hence work well in this application. Various different electron beam energies can 
be selected to appropriately treat the lesions. Due to the skin-sparing aspects of electron 
beam, the use of tissue equivalent bolus material to achieve full dose at the skin surface is 
standard. Micaily et al. reported on 18 patients with unilesional MF treated with electron 
beam at 30.6 Gy. (Micaily et al., 1998). The complete response rate was 100% and 2 patients 
failed out of field. The relapse free survival and overall survival rates were 86% and 100%, 
respectively. Wilson and colleagues reported on 21 patients treated with a median dose of 20 
Gy for stage IA MF.(Wilson et al., 1998). Local control was 75% at 10 years, and 85% for 
patients with unilesional disease. For patients that received >20 Gy, disease free survival 
was 91%. Dose recommendations are provided in Table 6.  
TSEBT is often considered for plaque (T2) and tumor (T3) cases due to the more guarded 
prognosis than T1 patients (10% of the skin involved). Because the response rates are so 
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good for skin-directed therapies, TSEBT is not commonly used for T1 cases. TSEBT is a 
specialized technique for radiotherapy departments and is not widely available. The typical 
dose is 36 Gy in 36 fractions given 4 times weekly for 9 weeks. There are 6 body positions with 
two gantry positions for each body position. Selective electron boosts are administered to areas 
that do not receive adequate dose: the scalp, perineum and soles of feet. Also selective 
blocking is performed to prevent excessive toxicity to the eyes, hands, feet and nails.  
In a Stanford study, a total of 180 patients with MF were treated with total skin electron-beam 
therapy (TSEBT) with or without topical nitrogen mustard. (Navi et al., 2011). The overall 
response rate was 100% while 60% of patients achieved a complete response (75% with T2 and 
47% with T3) and the overall survival was 59% (T2) and 40% (T3). Those patients with 
incomplete responses or relapse had a 100% overall response rate with a second round of 
TSEBT. The response durations in this study were 29 months for T2 disease and 9 months for 
T3 disease (P = 0.006). Attempts have been made to prolong the response rates after TSEBT; 
however, combined PUVA (Quiros et al., 1997), nitrogen mustard (Navi et al., 2011), and 
interferon-alpha 2b (Roberge et al., 2007) did not statistically prolong relapse time.  
Toxicities associated with TSEBT can be severe. Acute toxicities (defined as those during 
treatment and within 3 months of completion) include erythema, moist and dry 
desquamation, and pain. Given the severity of erythema and the resultant pain and 
discomfort, it is common to give a treatment break for a week or more during TSEBT. Late 
toxicities include generalized erythema (which can make it difficult for the clinician to 
separate from recurrence), telangiectasia, xerosis, secondary malignancies, and temporary 
and sometimes permanent loss of hair follicles, sweat glands, and nails. (KB, 2005). In our 
experience, hair loss is the main complaint from the patient, and is particularly distressing 
for females.  
EBRT is very useful as a palliative treatment for recurrent MF when isolated tumors are 
present. MF is relatively radiosensitive compared to other skin cancers and doses as low as 
400 cGy in 2 fractions can be very effective. Tumoritis has been known to occur with low 
doses of RT. This is secondary to prompt apoptosis resulting in rapid desquamation of the 
tumor site itself with relative sparing of the normal surrounding skin. Advanced MF lesions 
frequently ulcerate with RT and local wound care is essential to reduce the risk of infection. 
It is important to be prudent and patient and treat deep lesions with low, palliative doses (2 
Gy x 2 or 3 Gy x 2).  
6.2 Cutaneous B-Cell Lymphoma (CBCL) 
The cutaneous B-cell lymphomas (CBCL) are less common than are the cutaneous T-cell 
lymphomas and represent between 18.8% and 26.4% of all cutaneous lymphomas. (Fink-
Puches et al., 2002; Willemze et al., 1997). As opposed to most CTCL, CBCL presents as 
either solitary or paucilesional nodules on the skin with a red to violaceous color without 
any surface change such as scaling. The vast majority of CBCL are very low-grade 
malignancies with an excellent prognosis. It is important to make a distinction between 
primary cutaneous B-cell lymphomas which appear to arise in and stay in the skin as 
opposed to secondary cutaneous B-cell lymphoma where the skin is a secondary organ of 
involvement from a systemic lymphoma. Clinically the primary and secondary cutaneous B-
cell lymphomas can be indistinguishable, therefore, a search for a systemic lymphoma is 
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undertaken before the diagnosis of primary CBCL is confidently made. Radiotherapy is the 
mainstay of treatment for the majority of CBCL cases. 
6.2.1 Epidemiology 
Due to the rarity of CBCL, the actual incidence is difficult to determine, although there is a 
curious range in incidence across geographical areas. CBCL has been reported to comprise 
4.5% of all cutaneous lymphomas in the United States (Zackheim et al., 2000) to 26.4% of 
cases in Austria. (Fink-Puches et al., 2002). The varying regional incidence of CBCL is likely 
due to do differences in how CBCL is classified and entered into tumor registries. However, 
there is also good evidence that etiologic factors may well contribute to regional disparities 
in incidence. For example, it has been reported for many years now that infection with 
Borrelia burgdorferi has been linked with CBCL in Europe but a similar link has not been 
demonstrated in the U.S. (Cerroni et al., 1997; Goodlad et al., 2000).  
6.2.2 Etiology 
The hypothesis linking an underlying infection to CBCL is the notion that chronic antigenic 
stimulation may eventually lead to the selection of B-cell subclones over time. A similar 
hypothesis has been proposed for the development of small bowel lymphoma in patients 
with chronic bowel inflammation with celiac sprue or the development of MALT (mucosa 
associated lymphoid tissue) lymphomas arising in the gastric mucosa of patients with 
chronic Helicobactor pylori infection. (Fischbach et al., 2005). The reality is that the majority of 
cases of CBCL arise spontaneously and multiple attempts to pinpoint a specific cause have 
been unsuccessful. Putative etiologic agents include Borrelia spp.,  Epstein-Barr virus, or 
human herpes viruses. (Nagore et al., 2000; Zochling et al., 1998). Interestingly, there are 
cases of presumed benign reactive lymphoid hyperplasia (pseudolymphoma) simulating 
CBCL that have occurred secondary to drugs, vaccinations, arthropod bites, or chronic 
folliculitis. (Bergman, 2010). The question as to whether pseudolymphomas can progress to 
true CBCL has not been definitively answered, although it seems logical that with chronic 
antigenic stimulation, the ultimate selection of a B-cell clone remains a possibility. 
6.2.3 Clinical presentation 
There are many variants of CBCL, but the three entities discussed in this chapter are the two 
most common forms with indolent behavior (cutaneous follicle center cell lymphoma and 
cutaneous marginal zone lymphoma) and a more aggressive variant, large B-cell lymphoma 
of the leg as described in the European Organization for the Treatment of Cancer (EORTC) 
classification scheme. (Willemze et al., 1997).  
Primary cutaneous follicle center cell lymphoma (FCCL) and primary cutaneous marginal 
zone lymphoma (MZL) are frequently indistinguishable clinically and can only be separated 
histologically. Both usually present as either solitary or grouped red to plum-colored 
nodules that have a smooth surface without the scaling common to CTCL (See Figure 8a.). 
Compared to CTCL, the color tends to shift slightly on the spectrum from red to purple. The 
nodules are generally non-tender and are usually distributed on the head and neck or the 
torso. It is more uncommon to see lesions on the extremities. The prognosis for both entities 
is excellent. 
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Fig. 8a. Cutaneous B-cell lymphoma 
Large B-cell lymphoma of the leg (LBCLL) is one of the dermatologic diseases with a 
striking predilection for a specific anatomic site. The patients are almost uniformly elderly 
with a female to male predominance and the presentation is one of plum-shaped and plum-
colored nodules usually confined to one leg, most commonly below the knee. (Kerl & 
Cerroni, 1996; Vermeer et al., 1996). As the name implies, the B-cells show a striking large 
cell morphology compared to the relatively small-sized B-cells in FCCL and MZL. Unlike 
the other cutaneous B-cell lymphomas, it is common for nodules in LBCLL to ulcerate and 
lesions are usually grouped and multiple as opposed to solitary. The prognosis is much 
more guarded in LBCLL, with an estimated 5-year survival at about 50%. (Fink-Puches et 
al., 2002; Willemze, 1997). There are other systemic large B-cell lymphomas that can 
secondarily involve the skin of the leg, therefore, a search for an underlying systemic 
lymphoma is essential in these patients. (Cerroni, 2003).  
6.2.4 Pathology 
Follicle Center Cell Lymphoma (FCCL): 
Skin biopsies of FCCL have a fascinating appearance under light microscopy: a dermal 
infiltrate is comprised of lymphocytes simulating the germinal centers/follicles seen in 
lymph nodes (See Figure 8b). In about 25% of cases, the follicular architecture resembling 
the lymph node is classic, while the majority of cases will have less well-formed follicular  
 
Fig. 8b. Histology of cutaneous B-cell lymphoma, follicle center cell type. 
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architecture. (Cerroni et al., 2000). There is often an admixture of other inflammatory cells, 
including T-cells, histiocytes, eosinophils, and plasma cells. The B-cells express the B-cell 
markers CD-20 and CD-79a, but unlike nodal lymphomas, do not express the Bcl-2 protein. 
(Cerroni et al., 1994; Cerroni & Kerl, 1994). The tumors stain positively for kappa or lambda 
light chains but may or may not have an identifiable restriction of one light chain favoring 
another. Not present in FCCL is the 14;18 translocation normally found in nodal follicular 
lymphomas, and when present, should alert the clinician to search for an underlying 
systemic lymphoma. (Cerroni et al., 1994; Delia et al., 1989).  
Marginal Zone Lymphoma (MZL): 
The infiltrate in MZL is also dermal-based with sparing of the epidermis, but the follicular 
architecture is much less well-defined. There is, however, an infiltrate surrounding the 
neoplasm with pale-staining cells with abundant pale cytoplasm referred to by 
hematopathologists as “marginal zone cells.” These are centrocyte-like cells that are CD-20 
and –CD-79a positive, and unlike FCCL, Bcl-2 protein is usually positive. The majority of 
cases of MZL with demonstrate light chain restriction with a predominance of one of the 
light chains over the other.  
Large B-cell Lymphoma of the Leg (LBCLL): 
In contrast to FCCL and MZL, the infiltrates of LBCLL will abut the epidermis and can often 
percolate into the epidermis and simulate the epidermotropism of CTCL. (Cerroni et al, 
2009). The B-cells are larger and consist of immunoblasts, centroblasts, and large 
centrocytes. Cells express CD-20 and CD79a as expected but staining for the Bcl-2 protein is 
variable. Another pitfall may be the presence of CD30 positive large cells, which may 
simulate anaplastic large cell lymphoma derived from T-cells. In such cases, the CD30 does 
not have prognostic import as it does in anaplastic large cell lymphoma where its presence 
connotes a more favorable prognosis.  
6.2.5 Treatment 
Because most FCCL and MZL follow an indolent course, observation can be an acceptable 
practice with follow-up visits scheduled every six months or if new lesions arise. It has been 
our experience that many solitary lesions will actually involute with an incisional biopsy, 
which is to say that even if a small portion of the tumor is biopsied, the lesion may undergo 
spontaneous regression. In these cases it has been our practice to observe the lesion over 
time and treat only in cases of a local recurrence. In most cases, local RT is the first line 
treatment and provides high response rates coupled with excellent cosmesis and minimal 
morbidity.  
Radiotherapy was evaluated in a meta-analysis study of 460 patients with FCCL and the 
complete response rate was 99% (457/460), with doses ranging from 20-54 Gy but in general 
averaging above 30 Gy. The relapse rate was 30%, but not defined as to whether these were 
in-field vs. extra-field recurrences. That same study included a meta-analysis of 132 patients 
with MZL treated with radiotherapy, and again showed a 99% complete response rate 
(130/132), with average dosages between 30-45 Gy and margins ranging from 1 to 5 cm. 
(Senff et al., 2008). The recurrence rate was 46%, but again not specified if these were in-field 
www.intechopen.com
 
Modern Practices in Radiation Therapy 
 
236 
recurrences or other site recurrences. We have examined our own experience for patients 
with cutaneous B cell lymphoma. We identified 38 cases treated. The overall survival for 
the entire study population at 5 and 10 years was 97% and 78%, respectively, whereas 
disease-specific overall survival has not shown any deaths in the FCCL and MZL 
subgroups. Among patients that relapsed, in-field control was achieved in 82% of 
patients. Patients treated with other local therapies had a significant higher rate of failure 
(p=0.01). (Tward et al., 2009).  
Other treatment modalities included surgical excision for small solitary lesions, intralesional 
interferon-alpha, or intralesional or systemic rituximab therapy which is a monoclonal 
antibody to CD20. Due to ease of use and response rates, RT is the most commonly used 
first line treatment with doses recommended of 30 Gy with margins of 1 to 1.5 cm of 
uninvolved surrounding skin (See Table 6). (Senff et al., 2008).  
 
Table 6. Dose Recommendations for Cutaneous Lymphomas 
For LBCLL where the prognosis is much more guarded, the EORTC recommends that these 
cases be treated with multi-agent chemotherapy similar to treatment for diffuse large B-cell 
lymphoma. (Senff et al., 2008). Recommended is R-CHOP (rituximab plus 
cyclophosphamide, doxorubicin (Adriamycin), oncovin (Vincristine), and prednisone with 
or without adjuvant radiotherapy. Unfortunately, there are no controlled trials available to 
help make an informed decision in such cases. At our institution, the decision as to whether 
or not to add radiotherapy to R-CHOP is made in the setting of the Multidisciplinary 
Lymphoma Conference, and is based on the extent of the cutaneous disease. 
7. Conclusion 
Radiation therapy is an excellent treatment choice for a variety of skin cancers in a wide 
number of anatomic locations, which frequently offers high rates of cure with excellent 
cosmesis and provides patients an alternative to aggressive and often disfiguring surgery. 
RT also fills an important role as an adjunctive therapy when combined with other systemic 
agents with or without surgery, and should be included in the armamentarium of any 
multidisciplinary approach to skin cancer. Improved communication between academic 
training programs in dermatology and radiation oncology are needed to overcome historical 
biases that contribute to the underutilization of this very useful treatment modality.  
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